Novartis AG (NYSE:NVS) Stock Position Decreased by UMB Bank n.a.

UMB Bank n.a. reduced its stake in Novartis AG (NYSE:NVSFree Report) by 27.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,419 shares of the company’s stock after selling 2,823 shares during the period. UMB Bank n.a.’s holdings in Novartis were worth $722,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. increased its position in Novartis by 3.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 6,559 shares of the company’s stock worth $698,000 after buying an additional 232 shares during the period. AE Wealth Management LLC lifted its position in Novartis by 11.6% in the 2nd quarter. AE Wealth Management LLC now owns 6,316 shares of the company’s stock valued at $672,000 after purchasing an additional 656 shares during the last quarter. Frank Rimerman Advisors LLC acquired a new position in Novartis during the 2nd quarter valued at about $242,000. EverSource Wealth Advisors LLC grew its position in Novartis by 31.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,647 shares of the company’s stock worth $295,000 after purchasing an additional 634 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Novartis by 343.5% in the second quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock valued at $70,652,000 after purchasing an additional 509,567 shares during the period. 13.12% of the stock is owned by institutional investors.

Novartis Trading Up 2.2 %

Shares of Novartis stock opened at $99.69 on Wednesday. The business has a fifty day simple moving average of $100.44 and a 200-day simple moving average of $108.94. The firm has a market cap of $203.76 billion, a price-to-earnings ratio of 11.58, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. Novartis AG has a fifty-two week low of $92.35 and a fifty-two week high of $120.92. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVSGet Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The company had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same quarter last year, the firm posted $1.74 EPS. On average, equities analysts forecast that Novartis AG will post 7.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NVS. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets lifted their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and seven have issued a hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $121.50.

Read Our Latest Stock Report on NVS

About Novartis

(Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Read More

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.